Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL9308 | 0.81 | ALDH1A1 (0.43) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| Biphenyl SCHEMBL28349299 | 0.80 | AKT2 (0.38) | ALDH1A1KDM4EAKT1AKT2IDO1 | |
| Biphenyl SCHEMBL28359469 | 0.80 | ALDH1A1 (0.38) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| Tetrazole SCHEMBL28778836 | 0.79 | ALDH1A1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| Tetrazole SCHEMBL27729626 | 0.79 | ALDH1A1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| Biphenyl SCHEMBL1627148 | 0.79 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| Tetrazole SCHEMBL29023855 | 0.79 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| Biphenyl SCHEMBL27802159 | 0.79 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| Biphenyl SCHEMBL9158420 | 0.79 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| Tetrazole SCHEMBL28320883 | 0.79 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0971747-B1 | CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2005-12-28 | — | — | EP | claimed |
| US-6921525-B2 | Contrast agents | AMERSHAM HEALTH AS (NO) | 2005-07-26 | — | — | US | claimed |
| US-20030228254-A1 | Diagnosis of cardiovascular disorders | AMERSHAM HEALTH AS (NO) | 2003-12-11 | — | — | US | claimed |
| US-20010016587-A1 | Contrast agents | NYCOMED IMAGING AS | 2001-08-23 | — | — | US | claimed |
| EP-0971747-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2000-01-19 | — | — | EP | claimed |
| CN-101480390-A | Compound preparation containing Sartan and diuretics | BEIJING INST TECHNOLOGY (CN) | 2009-07-15 | — | — | CN | disclosed |
| CN-101361736-A | Compound of losartan or pharmaceutical salt thereof and calcium channel blockers or pharmaceutical salt thereof | BEIJING INST TECHNOLOGY (CN) | 2009-02-11 | — | — | CN | disclosed |
| CN-101347427-A | Compound of losartan compound or its medical salt and calcium channel blocker or its medical salt | BEIJING INST TECHNOLOGY (CN) | 2009-01-21 | — | — | CN | disclosed |
| US-7182934-B2 | Ultrasonic contrast agents; aqueous suspension | GE HEALTHCARE AS (NO) | 2007-02-27 | — | — | US | disclosed |
| EP-0971747-B1 | CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2005-12-28 | — | — | EP | disclosed |
| US-20050201930-A1 | Contrast agents | GE HEALTHCARE AS (NO) | 2005-09-15 | — | — | US | disclosed |
| US-6921525-B2 | Contrast agents | AMERSHAM HEALTH AS (NO) | 2005-07-26 | — | — | US | disclosed |
| US-20030228254-A1 | Diagnosis of cardiovascular disorders | AMERSHAM HEALTH AS (NO) | 2003-12-11 | — | — | US | disclosed |
| US-6524552-B2 | Imaging cardiovascular disorders | GE HEALTHCARE AS (NO) | 2003-02-25 | — | — | US | disclosed |
| US-20010016587-A1 | Contrast agents | NYCOMED IMAGING AS | 2001-08-23 | — | — | US | disclosed |
| US-6264914-B1 | CONTAINING IMIDAZOLE RING | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| EP-0971747-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998018496-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-05-07 | — | — | WO | disclosed |
| CN-1123276-A | Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds | KOTOBUKI SEIYAKU CO LTD (JP) | 1996-05-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030228254-A1 | Diagnosis of cardiovascular disorders | AGTR1, AGTR2, AGT | ENPP3 3419/4885ENPP1 3540/4885NPC1 2884/4885 |
| US-20010016587-A1 | Contrast agents | AGTR1, AGTR2, VIPR1 | ENPP3 3400/4885ENPP1 3492/4885NPC1 1915/4885 |
| US-20050201930-A1 | Contrast agents | AGTR1, AGTR2, VIPR1 | ENPP3 2649/4885ENPP1 3124/4885NPC1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.